NFKB1 and plasma cell myeloma: Therefore, despite the central role of NF-κB signalling in B-cell malignancies, the cis-regulatory mechanisms uncovered during aberrant non-canonical NF-κB activation may not be strictly limited to multiple myeloma and could be exploited across other cancers or inflammatory disorders.